The International Journal of Neuropsychopharmacology · 2004 · 312 citations · 8 references
MedicinePharmacologyPsychiatryMolecular PharmacologyNeuropharmacologyPsychopharmacologyAntidepressant PharmacologyAntidepressant PharmacotherapyAntidepressant TherapyBipolar Disorder PharmacotherapyBipolar DisordersDepression PharmacotherapyAntidepressant EfficacyAntidepressant MedicationsAntidepressant ResponseGlycogen Synthase Kinase 3 RegulationGlycogen Synthase Kinase 3 SignalingIntraperitoneal AdministrationLithium TreatmentMechanisms Of Antidepressant Action
The mechanism by which lithium exerts either its anti-manic or antidepressant effects remains to be fully elucidated. Although lithium inhibits the enzyme glycogen synthase kinase-3 (GSK-3) at concentrations that are relevant for treatment of bipolar disorder, it is unclear whether GSK-3-related mechanisms are responsible for its therapeutic effects in the treatment of this disease. We report that AR-A014418 (a selective GSK-3 inhibitor) induces behavioural changes that are consistent with the effects of antidepressant medications. Subacute intraperitoneal injections of AR-A014418 reduced immobility time in rats exposed to the forced swim test, a well-established model for antidepressant efficacy. In addition, the specificity of this effect is supported by our finding that AR-A014418 decreased spontaneous as well as amphetamine-induced activity. Taken together, these data support the hypothesis that lithium may exert its antidepressant effects through inhibition of GSK-3, and that novel small-molecule GSK-3 inhibitors may be useful for the treatment of bipolar disorder and depression.
8
Jean‐Martin Beaulieu, Tatyana D. Sotnikova, Wei‐Dong Yao et al. · Proceedings of the National Academy of Sciences · 2004 · 786 citations · Full text